Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2016
A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vitko Megan, Valerio Dana M, Rye Philip D, Onsøyen Edvar, Myrset Astrid H, Dessen Arne, Drumm Mitchell L, Hodges Craig A
Аннотация
BACKGROUND: Cystic fibrosis (CF) patients experience intestinal complications characterized by the accumulation of thick viscous mucus. CF mice were utilized to determine if a novel guluronate oligomer, OligoG, may be a potential therapy in reducing intestinal mucus and subsequent CF-related intestinal manifestations.
METHODS: Intestinal transit, intestinal histology, survival and growth were examined in wildtype and CF mice on regular water and OligoG.
CONCLUSIONS: OligoG improves intestinal transit and survival in CF mice by reducing the accumulation of intestinal mucus. OligoG's ability to directly bind mucin, disrupt mucin interaction and/or sequester calcium allowing for mucin expansion may explain the decrease in mucus accumulation.
METHODS: Intestinal transit, intestinal histology, survival and growth were examined in wildtype and CF mice on regular water and OligoG.
CONCLUSIONS: OligoG improves intestinal transit and survival in CF mice by reducing the accumulation of intestinal mucus. OligoG's ability to directly bind mucin, disrupt mucin interaction and/or sequester calcium allowing for mucin expansion may explain the decrease in mucus accumulation.